Approximately 80% of HCC cases arise in cirrhotic livers and different subtypes have been associated with specific molecular and cytogenetic abnormalities: the scirrhous subtype with TSC1/TSC2 mutations, the steatohepatitic subtype with frequent IL6/JAK/STAT activation, the macrotrabecular massive subtype possessed TP53 mutation and FGF19 amplification, and the DNAJB1-PRKACA fusion gene is pathognomonic for the fibrolamellar subtype [23]. Here, FGF19 is linked to hepatocellular carcinoma.